利妥昔单抗维持治疗套细胞淋巴瘤:系统评价与Meta分析
该系统评价与Meta分析检索PubMed、Embase和Cochrane对照试验中心注册库至2017年11月1日,纳入3项随机对照试验和4项观察性研究,评估利妥昔单抗维持(RM)治疗套细胞淋巴瘤的疗效。Meta分析显示,在自体干细胞移植(ASCT)后患者中,RM改善无进展生存(PFS)(HR=0.33,95%CI=0.23-0.49)和总生存(OS)(死亡HR=0.35,95%CI=0.17-0.69);在不适合ASCT且接受蒽环类诱导治疗的患者中,RM改善PFS(HR=0.38,95%CI=0.25-0.58)。
要点
- ASCT后RM改善PFS(HR=0.33,95%CI=0.23-0.49)和OS(死亡HR=0.35,95%CI=0.17-0.69)。
- 不适合ASCT且蒽环类诱导者,RM改善PFS(HR=0.38,95%CI=0.25-0.58)。
- RM在不适合ASCT和复发患者中的数据匮乏。
核心结论
- 对于接受诱导化学免疫治疗后进行ASCT的初治套细胞淋巴瘤患者,RM治疗似乎改善PFS和OS。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Embase和Cochrane对照试验中心注册库自建库至2017年11月1日,仅纳入全文文章。
- 纳入3项随机对照试验和4项观察性研究;6项研究比较RM与观察,1项比较RM与干扰素α。
- 采用Der Simonian-Laird随机效应模型汇总效应。
主要发现
- ASCT后患者Meta分析:RM改善PFS(HR=0.33,95%CI=0.23-0.49)和OS(死亡HR=0.35,95%CI=0.17-0.69)。
- 不适合ASCT且接受蒽环类诱导治疗患者Meta分析:RM改善PFS(HR=0.38,95%CI=0.25-0.58)。
关键数值与推荐
- ASCT后患者:PFS的HR=0.33(95%CI=0.23-0.49),OS的死亡HR=0.35(95%CI=0.17-0.69)。
- 不适合ASCT且蒽环类诱导患者:PFS的HR=0.38(95%CI=0.25-0.58)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出RM在不适合ASCT患者和复发疾病患者中的作用数据匮乏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mantle cell lymphoma is characterized by relapse and progressive disease, despite initial response to chemoimmunotherapy. We conducted a systematic review and meta-analysis to determine the efficacy of rituximab maintenance (RM) therapy in patients with mantle cell lymphoma. We searched PubMed, Embase and Cochrane Central Register of Controlled Trials from database inception through November 1, 2017. Only full-text articles were included. Prespecified data elements were extracted from each trial. Outcomes of interest included progression-free survival (PFS) and overall survival (OS). The overall effect was pooled using the Der Simonian-Laird random effects model. Three randomized controlled trials and four observational studies met our inclusion criteria and were identified in the analyses. Six studies compared RM therapy to observation, and one compared RM therapy to interferon alfa. Meta-analysis evaluating outcomes of patients treated after ASCT revealed that RM improved for both PFS (HR = 0.33, 95% CI = 0.23-0.49) and OS (HR of death = 0.35, 95% CI = 0.17-0.69). A second meta-analysis of studies evaluating outcomes of patients who are ASCT-ineligible treated with anthracycline-based induction therapy revealed that RM improved PFS (HR = 0.38, 95% CI = 0.25-0.58). There is a paucity of data on the role of RM in ASCT-ineligible patients and those with relapsed disease. Overall, RM therapy appears to improve PFS and OS in previously untreated patients with mantle cell lymphoma who undergo induction chemoimmunotherapy followed by ASCT.
引用
- Hilal T, Wang Z, Almader-Douglas D, et al. Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and meta-analysis. Am J Hematol. 2018. PMID: 30033656. doi:10.1002/ajh.25226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。